New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
08:03 EDTESRX, WAGWalgreen reports January SSS up 3.7%, reports January sales $6.15B
Total front-end sales increased 1.3% compared with the same month in fiscal 2012, while comparable store front-end sales decreased 0.4%. Customer traffic in comparable stores decreased 2.8% while basket size increased 2.4%. The company said the percentage of Express Scripts customers filling prescriptions in its pharmacies continued to increase in January. January pharmacy sales increased by 8.7%, while comparable store pharmacy sales increased 6.2%. Sales in comparable stores increased by 3.7% in January.
News For WAG;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
10:28 EDTESRXLeerink pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
10:01 EDTESRXOn the Fly: Analyst Initiation Summary
Subscribe for More Information
07:36 EDTESRXExpress Scripts initiated with an Equal Weight at Stephens
Subscribe for More Information
January 20, 2015
06:44 EDTESRXExpress Scripts downgraded to Neutral from Buy at UBS
Subscribe for More Information
January 13, 2015
12:17 EDTESRXExpress Scripts CEO says new cholesterol lowering drugs 'pretty expensive'
12:15 EDTESRXExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTESRXExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use